And while prostate-specific antigen (PSA) has long been used as a marker of biochemical activity and has shown to have some level of clinical validity and predictive risk of prostate cancer-specific death [14,15], other studies show this relationship might not be so clear, especially with higher PSA levels [16]. The gene discussed is KLK3; the disease is prostate carcinoma.